ReviewNature reviews. Gastroenterology & hepatology2018
Novel perspectives in the management of decompensated cirrhosis.
Review in Nature reviews. Gastroenterology & hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Albumin for people with liver cirrhosis and bacterial infections.The Cochrane database of systematic reviews · 2026Pooled it
- Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis.The Cochrane database of systematic reviews · 2019Pooled it
- Comment on "Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection".Journal of gastroenterology · 2026Article
- Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection.Journal of gastroenterology · 2026Article
- DYSBIOSIS IN ACUTE-ON-CHRONIC LIVER FAILURE - FROM A PATHOPHYSIOLOGICAL COMPONENT TO A THERAPEUTIC TARGET.Arquivos de gastroenterologia · 2026Review
- Association between the C-reactive protein-triglyceride-glucose index (CTI) and the risk of acute kidney injury in critically ill patients with cirrhosis.BMC nephrology · 2025Article
- Interaction of inflammation and portal hypertension in cirrhosis progression.Nature reviews. Gastroenterology & hepatology · 2025Review
- Oral curative therapeutic study of N-nitrosodiethylamine-induced mouse liver damage of chitosan-coated ursolic acid niosomes.Scientific reports · 2025Article
- Risk factors and prognostic impact of new decompensated events in hospitalized patients with decompensated cirrhosis.BMC gastroenterology · 2024Article
- Gut liver brain axis in diseases: the implications for therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- Improving Outcomes in Hepatorenal Syndrome-Acute Kidney Injury With Early Diagnoses and Implementation of Approved Treatment Regimens.Gastroenterology & hepatology · 2023Article
- How non-alcoholic fatty liver disease and cirrhosis affect the heart.Hepatology international · 2023Review
- Use of albumin infusion for cirrhosis-related complications: An international position statement.JHEP reports : innovation in hepatology · 2023Article
- A salivary biomarker panel to detect liver cirrhosis.iScience · 2023Article
- Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2023Review
- Therapeutic possibilities of gut microbiota modulation in acute decompensation of liver cirrhosis.World journal of hepatology · 2023Review
- Review
- Development and validation of a prognostic nomogram for decompensated liver cirrhosis.World journal of clinical cases · 2022Article
- Albumin administration in patients with cirrhosis: Current role and novel perspectives.World journal of gastroenterology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current approaches to the management of patients with decompensated cirrhosis are based on targeted strategies aimed at preventing or treating specific complications of the disease. The improved knowledge of the pathophysiological background of advanced cirrhosis, represented by a sustained systemic inflammation strictly linked to a circulatory dysfunction, provides a novel paradigm for the management of these patients, with the ambitious target of modifying the course of the disease by preventing the onset of complications and multiorgan failure; these interventions will eventually improve patients' quality of life, prolong survival and reduce health-care costs. Besides aetiological treatments, these goals could be achieved by persistently antagonizing key pathophysiological events, such as portal hypertension, abnormal bacterial translocation from the gut, liver damage, systemic inflammation, circulatory dysfunction and altered immunological responses. Interestingly, in addition to strategies based on new therapeutic agents, these targets can be tackled by employing drugs that are already used in patients with cirrhosis for different indications or in other clinical settings, including non-absorbable oral antibiotics, non-selective β-blockers, human albumin and statins. The scope of the present Review includes reporting updated information on the treatments that promise to influence the course of advanced cirrhosis and thus act as disease-modifying agents.
Indexed as
Identifiers
30026556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.